Last reviewed · How we verify

NCT04612582

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Status unknown Phase 4 Last updated 3 November 2020
What this trial tests

Phase 4 trial testing Thalidomide in Immunoglobulin Light-Chain Amyloidosis in 70 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
31 January 2023
30 June 2023

Quick facts

Lead sponsorGuangdong Provincial People's Hospital
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment70
Start date1 January 2020
Primary completion31 January 2023
Estimated completion30 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangdong Provincial People's Hospital

Who can join

Adults 18 to 80, any sex, with Immunoglobulin Light-Chain Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Research Objective:At present, there is no standard therapeutic regimen for monoclonal immunoglobulin light chain (AL) amyloidosis in the world. To compare the efficacy and safety of the regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard treatment for the disease. Research Design:This study was designed as a prospective, randomized and controlled clinical study. Patients who meet the inclusion criteria of this study will be randomized to the BTD scheme group or BCD scheme group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Thalidomide

Trials testing the same drug.

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing